Source: Eur Respir J 2009; 33: 1503-1506
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Borie R., Debray M-P., Laine C., Aubier M., Crestani B.. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33: 1503-1506

Member's Comments

No comment yet.

Related content which might interest you: Plasmapheresis for treatment of pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1220-1222 Year: 2009 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis Source: Eur Respir J 2006; 27: 585-593 Year: 2006 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Granulocyte-macrophage colony stimulating factor inhalation therapy as a treatment for pulmonary alveolar proteinosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 An open-label trial of rituximab therapy in pulmonary alveolar proteinosis Source: Eur Respir J 2011; 38: 1361-1367 Year: 2011 Alveolar lipoproteinosis syndromes Source: Eur Respir Mon 2011; 54: 171-186 Year: 2011 Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 The analysis of alveolar macrophage form in secondary pulmonary alveolar proteinosis complicated with myelodysplastic syndrome. Source: International Congress 2017 – Rare diseases Year: 2017 PAS-negative pulmonary alveolar proteinosis Source: Annual Congress 2008 - Rare clinical cases Year: 2008 Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 The role of apoptosis in idiopathic pulmonary alveolar proteinosis Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006